PARSIPPANY, N.J., July 17 /PRNewswire/ -- Dynova Laboratories has
announced the acquisition of SiCap Industries LLC and its innovative line of
capsaicin-based products marketed under the Sinus Buster brand. This is the
initial acquisition for Dynova Laboratories, a new company with expertise in
identifying and building successful OTC brands. Dynova's objective is to
bring to market unique and innovative natural supplements that fulfill
important, but as yet unmet, consumer needs. All Dynova product launches will
meet the company's stringent safety and efficacy criteria, which were
established to ensure a high level of user satisfaction. Dynova is backed by
Aisling Capital, a private equity fund investing in life sciences companies.
'Today's consumers are redefining the healthcare market as they
increasingly turn to natural products to treat a variety of conditions and
improve their wellbeing. SiCap fulfills these needs with its novel Sinus
Buster line of products,' according to Dynova Laboratories CEO Lynne
Millheiser-Swanbeck. 'While SiCap is the first in the Dynova family of
companies, we are aggressively looking for other unique, natural and effective
products and technologies.'
SiCap founder Wayne Perry commented, 'Dynova Laboratories has the
marketing muscle and consumer insight, along with the clinical expertise and
financial resources necessary to build Sinus Buster into a leading brand in
the sinus, allergy and headache marketplace.'
Perry first realized the value of capsaicin for headaches when he was
sprayed with pepper spray as part of a self-defense demonstration on a local
Fox news show. At the time, Perry happened to be suffering from one of his
frequent, painful cluster headaches. 'I was astounded to realize my headache
was gone immediately after being sprayed in the face,' he said. Perry went on
to research and develop Sinus Buster pepper-based nasal spray, which he
subsequently built into a significant Internet-based business.
The Dynova team has extensive experience in both the consumer healthcare
and natural supplement industries. Millheiser-Swanbeck joined Dynova from
Novartis where she was senior vice president for the North American OTC
division. Prior to that, she held a variety of senior level positions at the
Warner-Lambert Company and Pfizer, including U.S. head of marketing and sales
and as general manager in southern Europe. Jeff Vernimb, vice president,
Marketing and Sales, for Dynova was vice president of Global Marketing for
Cardinal Health's Oral Technologies group and also held the title of vice
president, Marketing for Novartis's OTC division. Jennifer Cooper, Dynova's
vice president of Research & Development, has nearly two decades of experience
in the dietary supplement and functional food categories, including stints at
Twin Laboratories and Solgar.
About Dynova Laboratories
Dynova Laboratories is an emerging natural products company dedicated to
improving consumers' health and wellbeing with safe, clinically effective
natural therapies. Dynova's unique mission is to identify small, promising
brands, companies and technologies for licensing or acquisition and provide
the clinical, marketing, packaging and sales support necessary for success in
the dietary or natural supplements category. Based in Parsippany, New
Jersey, the company is headed by a team experienced in the consumer healthcare
and natural supplement industries. It is backed by Aisling Capital, a leading
private equity fund that invests in life sciences companies. For more
information visit www.dynovalabs.com or call 973.968.7923.
SOURCE Dynova Laboratories
